BA
RARE icon

Bellwether Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bellwether Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31
Closed -$3K – 466
2021
Q1 		$3K Buy
31
+2
+7% +$272 ﹤0.01% 333
2020
Q4 		$4K Buy
+29
New +$3.44K ﹤0.01% 281

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bellwether Advisors's RARE Position: Q2 2021 in Review

Bellwether Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 31 shares — an estimated $3K sold.

Bellwether Advisors first reported a position in RARE in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Bellwether Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Bellwether Advisors sold 31 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $3K.
  • Bellwether Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 2 quarters.
  • Bellwether Advisors's Ultragenyx Pharmaceutical position peaked at $4K in Q4 2020.
  • 241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Bellwether Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.